Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system.

Parnes, Aric; Leblebjian, Houry; Hamilton, Joanna; Smith, Sydney; Laubach, Jacob; Berliner, Nancy

Parnes, Aric; Leblebjian, Houry; Hamilton, Joanna; Smith, Sydney; Laubach, Jacob; Berliner, Nancy.

Afiliación

Parnes A; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Leblebjian H; Department of Clinical Pharmacy, Dana-Farber Cancer Institute, Boston, MA, USA.
Hamilton J; Department of Quality and Patient Safety, Dana-Farber Cancer Institute, Boston, MA, USA.
Smith S; Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA.
Laubach J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Berliner N; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

J Oncol Pharm Pract ; 28(2): 421-424, 2022 Mar.

Article en En | MEDLINE | ID: mdl-33611974

Asunto(s)

Mieloma Múltiple; Farmacia; Tromboembolia Venosa; Anticoagulantes/uso terapéutico; Humanos; Agentes Inmunomoduladores; Mieloma Múltiple/complicaciones; Mieloma Múltiple/tratamiento farmacológico; Factores de Riesgo; Tromboembolia Venosa/prevención & control

Palabras clave

Venous thromboembolism prevention; multiple myeloma; prophylaxis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Farmacia / Tromboembolia Venosa / Mieloma Múltiple Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google